22.3 Septic Arthritis & Acute Microcrystalline Crises

Acute Septic Arthritis: Pathogenesis & Microbiology

Septic (bacterial) arthritis is a medical and orthopedic emergency carrying a 10% to 15% in-hospital mortality rate and permanent joint dysfunction in up to 50% of survivors. Rapid recognition is paramount: bacterial proliferation within a closed synovial space induces rapid, irreversible destruction of articular hyaline cartilage within 24 to 48 hours.

Pathophysiology of Joint Destruction

• Absence of Synovial Basement Membrane: The synovial membrane is highly vascularized but lacks a protective limiting basement membrane. Consequently, circulating bacteria readily extravasate across synovial capillaries into the joint space during transient or sustained bacteremia.
• The Inflammatory Destruction Cascade:
  1. Bacteria proliferate within synovial fluid, releasing endotoxins, peptidoglycans, and bacterial proteases.
  2. Synovial macrophages and infiltrating neutrophils release massive surges of proinflammatory cytokines (TNF-alpha, IL-1beta, IL-6, and IL-8).
  3. Recruited polymorphonuclear neutrophils (PMNs) release destructive lysosomal enzymes and matrix metalloproteinases (MMPs) that directly digest collagen fibers and proteoglycans within the articular cartilage matrix.
  4. Massive intra-articular purulent exudate accumulates, dramatically elevating intra-articular hydrostatic pressure. High pressure exceeds subchondral capillary perfusion pressure, inducing capillary tamponade, microvascular subchondral bone ischemia, and aseptic avascular necrosis.

Route of Infection

1. Hematogenous Seeding (Single Most Common Route, >90% of cases): Secondary to occult bacteremia from skin/soft-tissue infections, intravenous drug use, dental procedures, urinary tract infections, or central venous catheters.
2. Direct Penetrating Inoculation: Accidental puncture wounds, animal or human bites, arthrocentesis, intra-articular steroid injections, or arthroscopic surgery.
3. Contiguous Spread: Direct extension from adjacent osteomyelitis (particularly in infants where transphyseal vessels connect the metaphysis to the epiphysis), septic bursitis, or deep periarticular soft-tissue abscesses.

Microbiology of Septic Arthritis

The Dual Syndromes of Disseminated Gonococcal Infection (DGI)

Neisseria gonorrhoeae manifests in two distinct clinical presentations:

1. The Classic Triad of DGI (Bacteremic Form):
   • Migratory Polyarthralgias: Asymmetric joint pain migrating across wrists, elbows, knees, and ankles;
   • Tenosynovitis: Simultaneous inflammation of multiple tendon sheaths, characteristically involving the dorsum of the wrists, fingers, and Achilles tendon;
   • Dermatitis: Painless, sparse (typically 2 to 10 lesions) vesiculopustular, petechial, or hemorrhagic necrotic pustules on an erythematous base located on the distal extremities.
   • Diagnostic Rule: Synovial fluid cultures in this bacteremic form are frequently negative (<25% sensitivity). Diagnosis requires Nucleic Acid Amplification Testing (NAAT) from mucosal sites: urogenital, pharyngeal, and rectal swabs.
2. Purulent Gonococcal Monoarthritis (Septic Form):
   • Presents as an acute, isolated, purulent monoarthritis (knee, wrist, or ankle) without classic tenosynovitis or cutaneous pustules. Synovial fluid culture is positive in approximately 50% of cases.

---

Diagnostic Evaluation & Arthrocentesis Master Matrix

Clinical Presentation

• Acute Monoarticular Pain: Rapid onset (hours to days) of excruciating, constant pain, localized to a single large joint: Knee (>50% of cases), hip (20%), shoulder (8%), ankle (7%), or wrist (6%).
• The Hallmark Physical Exam Finding: Dramatic, painful restriction of BOTH ACTIVE AND PASSIVE RANGE OF MOTION. The patient maintains the joint in a position of maximum capsular volume (e.g., knee flexed at 30 to 45 degrees) and vigorously refuses even minor passive joint movement (e.g., "log-rolling" of the hip produces agony).
• Local Signs: Large joint effusion, palpable warmth, erythema, and marked localized tenderness.
• Systemic Signs: Low-grade or spiking fevers and tachycardia in 60% to 80% of patients. Caution: Up to 20% to 30% of elderly, uremic, cirrhotic, or immunosuppressed patients are completely afebrile and fail to demonstrate significant peripheral leukocytosis.

[!IMPORTANT] THE MANDATORY ARTHROCENTESIS IMPERATIVE: Arthrocentesis (joint aspiration) must be performed IMMEDIATELY in every patient presenting with an acute, unexplained monoarticular joint effusion prior to the administration of systemic antibiotics. Delaying aspiration or administering antibiotics before obtaining synovial fluid dramatically lowers culture sensitivity and impedes pathogen-directed antimicrobial therapy.

Synovial Fluid Analysis Master Table

Additional Synovial Fluid Parameters

• Gram Stain: Positive in 50% to 70% of staphylococcal/streptococcal infections, but positive in only <25% of gonococcal infections. A negative Gram stain NEVER excludes septic arthritis.
• Synovial Lactate: Elevated (>10 to 11 mmol/L) demonstrates >90% sensitivity for bacterial arthritis.
• The "Crystals Do Not Rule Out Infection" Rule:
  • The identification of monosodium urate or calcium pyrophosphate crystals under polarized light DOES NOT rule out concurrent septic arthritis.
  • Septic arthritis and crystal-induced synovitis can coexist within the same joint ("coexistent septic and crystal arthritis"). If synovial fluid shows >50,000 WBCs/µL or if clinical suspicion for infection is high, full empiric antimicrobial therapy must be continued pending final 48-hour bacterial cultures.

---

Emergency Therapeutic Management of Septic Arthritis

                  SEPTIC ARTHRITIS MANAGEMENT PROTOCOL

  ┌────────────────────────────────────────────────────────────────────────┐
  │ STEP 1: IMMEDIATE DIAGNOSTIC ARTHROCENTESIS                            │
  │ • Send fluid for: Cell count + diff, Gram stain, Aerobic/Anaerobic     │
  │   cultures, Polarized microscopy (crystals), Glucose, Lactate          │
  │ • Obtain 2 sets of peripheral blood cultures                           │
  └───────────────────────────────────┬────────────────────────────────────┘
                                      │
                                      ▼
  ┌────────────────────────────────────────────────────────────────────────┐
  │ STEP 2: IMMEDIATE EMPIRIC INTRAVENOUS ANTIMICROBIALS                   │
  │ • Initiate immediately AFTER joint fluid aspiration is completed       │
  │ • IV Vancomycin 15-20 mg/kg q8-12h (MRSA & Gram-positives)             │
  │   PLUS                                                                 │
  │ • IV Ceftriaxone 1-2 g daily (N. gonorrhoeae & Gram-negatives)         │
  │ • If IVDU / Pseudomonas risk: Substitute Ceftriaxone with Cefepime 2g  │
  └───────────────────────────────────┬────────────────────────────────────┘
                                      │
                                      ▼
  ┌────────────────────────────────────────────────────────────────────────┐
  │ STEP 3: URGENT ORTHOPEDIC JOINT DECOMPRESSION                          │
  │ • Emergent orthopedic surgical consultation                            │
  │ • Modalities: Arthroscopic debridement & lavage (knee/shoulder) OR     │
  │   Open arthrotomy (hip, difficult joints) OR Serial daily needle aspir │
  │ • Antibiotics alone CANNOT sterilize an infected, pressurized joint    │
  └────────────────────────────────────────────────────────────────────────┘

1. Empiric Intravenous Antimicrobial Therapy

Empiric antimicrobial therapy must be initiated intravenously immediately following diagnostic arthrocentesis:

• Standard Empiric Combination:
  • Vancomycin 15 to 20 mg/kg IV every 8 to 12 hours (targets MRSA, MSSA, and penicillin-resistant Streptococcus species);
  • PLUS Ceftriaxone 1 g to 2 g IV daily (targets Neisseria gonorrhoeae and community-acquired Gram-negative bacilli).
• High Risk for Pseudomonas aeruginosa / Nosocomial Gram-Negatives (Injection drug use, institutionalized patients, indwelling urinary catheter):
  • Substitute Ceftriaxone with an antipseudomonal beta-lactam: Cefepime 2 g IV every 8 hours OR Piperacillin-tazobactam 4.5 g IV every 6 hours.
• Pathogen-Directed De-escalation (Once cultures and susceptibilities return):
  • Methicillin-Susceptible S. aureus (MSSA): De-escalate to Cefazolin 2 g IV every 8 hours or Nafcillin 2 g IV every 4 hours (superior bactericidal clearance compared to vancomycin).
  • Neisseria gonorrhoeae: Ceftriaxone 1 g to 2 g IV daily for 7 to 14 days.
  • Streptococcus pneumoniae / pyogenes: Penicillin G 2 to 4 million units IV every 4 hours or Ceftriaxone 2 g IV daily.
  • Duration: Typically 3 to 4 weeks of targeted antibiotic therapy (minimum 2 weeks IV, followed by bioavailable oral therapy based on clinical resolution and normalizing inflammatory markers [ESR/CRP]).

2. Urgent Joint Decompression: Orthopedic Modalities

Systemic antimicrobials cannot penetrate an infected joint space with elevated hydrostatic pressure to sterilize purulent exudate. Evacuation of purulent fluid is mandatory:

• Arthroscopic Debridement & Lavage: Treatment of choice for the knee, shoulder, and ankle; allows direct visualization, lysis of fibrinous loculations, thorough debridement of inflamed necrotic synovium, and copious high-volume irrigation.
• Open Arthrotomy: Required for hip septic arthritis (due to deep anatomical location and high risk of avascular necrosis of the femoral head), joints with extensive osteomyelitis or hardware, or cases where arthroscopy fails to clear infection.
• Serial Closed-Needle Aspiration: Reserved for easily accessible superficial joints (e.g., knee) in patients responding rapidly to medical therapy or poor surgical candidates unfit for general anesthesia; performed daily until effusions cease to reaccumulate and synovial fluid cultures become sterile.

---

Acute Microcrystalline Crises: Gout versus CPPD (Pseudogout)

Crystal arthropathies represent acute, excruciating, inflammatory mono- or oligo-arthritides caused by the intra-articular precipitation of microcrystals that trigger the innate immune system.

               POLARIZED LIGHT MICROSCOPY CRYSTAL PHYSICS

        MONOSODIUM URATE (GOUT)             CALCIUM PYROPHOSPHATE (CPPD)
  ┌─────────────────────────────────┐     ┌─────────────────────────────────┐
  │ • Shape: Needle-shaped, sharp   │     │ • Shape: Rhomboid / Parallelepip│
  │ • Birefringence: STRONGLY NEG   │     │ • Birefringence: WEAKLY POS     │
  │ • PARALLEL to axis: BRIGHT YELLOW│    │ • PARALLEL to axis: BLUE        │
  │ • PERPENDICULAR: BLUE           │     │ • PERPENDICULAR: YELLOW         │
  └─────────────────────────────────┘     └─────────────────────────────────┘

1. Gout (Monosodium Urate Crystal Deposition)

• Pathogenesis:
  • Chronic hyperuricemia (serum urate >6.8 mg/dL, the physiological solubility limit at 37°C) leads to the nucleation and precipitation of monosodium urate (MSU) monohydrate crystals in synovial fluid, synovial membranes, and periarticular tissues.
  • Phagocytosis of MSU crystals by intra-articular macrophages triggers the NLRP3 inflammasome complex.
  • Activated NLRP3 activates caspase-1, which cleaves pro-interleukin-1β into active interleukin-1β (IL-1β).
  • Massive IL-1β secretion activates vascular endothelial cells, triggering intense chemotactic recruitment of polymorphonuclear neutrophils into the joint space, resulting in severe acute synovitis.
• Clinical Presentation:
  • Explosive, agonizing pain that characteristically peaks in intensity within 12 to 24 hours of onset, often awakening the patient from sleep in the early morning hours.
  • Podagra (1st Metatarsophalangeal Joint): Involved in >50% of initial attacks and >80% of patients over their lifetime. Other frequent sites: midfoot (instep), ankle, knee, and olecranon bursa.
  • Marked localized erythema, swelling, warmth, and exquisite hypersensitivity (the touch of a bedsheet or gentle airflow elicits unbearable pain). Periarticular erythema frequently mimics cellulitis.
• Polarized Light Microscopy:
  • Demonstrates needle-shaped, intensely negatively birefringent crystals.
  • Optical Physics Under Red Compensator: When the long axis of the needle-shaped crystal is oriented parallel to the slow axis of the red compensator filter, the crystal appears bright yellow. When rotated perpendicular to the compensator axis, the crystal appears blue.
• Serum Urate Levels During an Acute Flare:
  • Critical Board Exam Fact: Serum urate concentrations are completely normal in up to 30% to 40% of patients during an acute gout attack. High circulating levels of systemic cortisol and IL-6 during acute inflammation induce renal uricosuria, lowering serum urate. A normal serum uric acid level NEVER excludes acute gout; definitive diagnosis requires polarizing microscopy of synovial fluid.

Evidence-Based Acute Gout Flare Management

Pharmacologic therapy must be initiated as early as possible (ideally within 24 hours of symptom onset). Three first-line anti-inflammatory classes demonstrate equal efficacy; selection depends upon patient comorbidities:

1. Nonsteroidal Anti-Inflammatory Drugs (NSAIDs):
   • Regimen: Full anti-inflammatory doses: Indomethacin 50 mg PO TID or Naproxen 500 mg PO BID for 5 to 7 days, tapering rapidly after symptom resolution.
   • Contraindications: Chronic kidney disease (eGFR <60 mL/min), active peptic ulcer disease, severe heart failure, cirrhosis, and concurrent therapeutic anticoagulation.
2. Colchicine:
   • Mechanism: Inhibits microtubule polymerization by binding tubulin, blocking neutrophil chemotaxis, adhesion, and inflammasome activation.
   • Low-Dose FDA Dosing Protocol: 1.2 mg PO at the first sign of flare, followed by 0.6 mg PO 1 hour later (total dose: 1.8 mg over 1 hour). After 12 hours, continue 0.6 mg PO once or twice daily until the flare resolves.
   • Efficacy Window: Must be initiated within 36 hours of flare onset to provide clinical benefit.
   • Toxicity & Drug Interactions: High doses cause severe diarrhea, vomiting, and abdominal cramping. Dose must be reduced in moderate-to-severe renal impairment. Strictly contraindicated in patients receiving strong CYP3A4 inhibitors (e.g., clarithromycin, ketoconazole) or P-glycoprotein inhibitors (e.g., cyclosporine) due to risks of fatal colchicine neuromyopathy and bone marrow suppression.
3. Corticosteroids:
   • First-line choice in patients with renal insufficiency, heart failure, or gastrointestinal ulcer disease where NSAIDs and colchicine are contraindicated.
   • Oral Regimen: Prednisone 30 to 40 mg PO daily for 5 days, or tapered over 7 to 10 days.
   • Intra-Articular Injection: Triamcinolone acetonide (10 to 40 mg) injected directly into the joint space is highly effective for isolated monoarticular flares (e.g., knee) once joint infection has been definitively excluded via prior fluid analysis.

Critical Board Exam Rules Governing Urate-Lowering Therapy (ULT)

[!CAUTION] THE CARDINAL RULES OF ALLOPURINOL MANAGEMENT DURING A FLARE:

1. DO NOT INITIATE OR TITRATE URATE-LOWERING THERAPY DURING AN ACUTE GOUT FLARE. Rapid shifts in serum urate concentrations alter crystal surface solubility dynamics, promoting crystal fracturing and shedding into the synovial space, which paradoxically prolongs and severely intensifies the acute inflammatory attack. Wait at least 2 to 4 weeks after complete clinical resolution of the flare before starting allopurinol or febuxostat, and always co-prescribe anti-inflammatory flare prophylaxis (e.g., low-dose colchicine 0.6 mg daily or naproxen 250 mg BID) for 3 to 6 months.
2. DO NOT STOP CHRONIC ALLOPURINOL IF THE PATIENT IS ALREADY TAKING IT. If a patient experiences a breakthrough acute flare while taking chronic allopurinol, continue the baseline allopurinol dose without interruption. Abruptly discontinuing allopurinol triggers a sharp rebound surge in serum urate, precipitating further crystal instability and markedly prolonging the flare. Treat the acute flare vigorously with NSAIDs, colchicine, or steroids while maintaining chronic allopurinol unchanged.